Table 3. Response and survival outcomes by trial interventions.

	Platinum-based regimen				Number of drugs
	Yes (N=216)		No (N=217)		2-Drugs (N=212)		3-Drugs (N=221)
	No.	%	No.	%	No.	%	No.	%
Best overall response a
CR	4	2	4	2	4	2	4	2
PR	62	29	48	22	57	27	53	26
SD	77	36	71	33	69	33	79	35
PD	29	14	39	18	34	16	34	16
NE	41	19	52	24	47	22	46	22
Adjusted percentage of CR+PR (95% CI)	31% (25–37%)		24% (19–30%)		29% (23–35%)		26% (21–33%)
Adjusted OR (95% CI), P-value	0.72 (0.47–1.10), P=0.124				0.86 (0.56–1.32), P=0.487
PFS
Number of events	201		213		201		213
1-Year and 2-year adjusted probability	19.7% and 7.6%		12.9% and 3.9%		15.8% and 5.3%		16.5% and 5.7%
Adjusted median (95% CI), months	6.4 (5.3–7.1)		4.9 (4.4–5.8)		5.6 (4.7–6.6)		5.7 (4.8–6.7)
Adjusted HR (95% CI), P-value	1.26 (1.04–1.53), P=0.020				0.98 (0.81–1.19), P=0.820
OS
Number of events	190		209		195		204
1-Year and 2-year adjusted probability	47.9% and 20.7%		40.6% and 14.5%		44.8% and 17.9%		43.8% and 17.0%
Adjusted median (95% CI), months	11.3 (9.8–12.7)		9.7 (8.7–10.8)		10.4 (9.4–12.2)		10.3 (9.2–11.8)
Adjusted HR (95% CI), P-value	1.23 (1.01–1.49), P=0.044				1.03 (0.85–1.25), P=0.781

Abbreviations: CI=confidence interval; CR=complete response; HR=hazard ratio; NE=not evaluated; OR=odds ratio; OS=overall survival; PD=progressive disease; PFS=progression-free survival; PR=partial response; SD=stable disease.

^aSix patients without measurable disease at randomisation were excluded from the analysis of best overall response.